The newly launched site will also provide details on the effect that food intake, exercise, and medication can have on control glucose levels along with color-coded graph and charts which are focused at usability, bolus tracking features, amplified insulin pump reports, and statistics.
Denmark-based, Novo Nordisk developed a drug that stimulates insulin productions called semaglutide a class of drugs which categorized in GLP-1s. The new oral diabetes medicine is a better lowering blood sugar levels compared to the existing drug.
The appearance and smell of urine could intimate a lot about the person’s health. Due to the presence of waste contents in urine, it might look or smell unusual.
Diabetes Australia's (the third oldest diabetes association in the world) latest figures show that over 200,000 women have suffered gestational diabetes during the last 10 years and is expected to exceed 500,000 within the next decade. Gestational diabetes can be fatal if untreated and could likely lead to overweight babies, premature births, as well as PreEclampsia.
Lately, Biotech and immunotherapy have been widely covered by media, but there’s more to healthcare than taking leaps of faith on new tech. New companies are addressing administrative functions, personalized medicine, and proactive wellness in their approach to the health industry.
Use of an artificial pancreas is associated with better control of blood sugar levels for people with type 1 diabetes compared with standard treatment, finds a review of the available evidence published by The BMJ today.
First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.
Eli Lilly and Company and Sigilon Therapeutics, a privately held biopharmaceutical company, announced a global collaboration to develop encapsulated cell therapies for potentially treating Type 1 diabetes. The deal is worth up to $473 million. Sigilon is focused on discovering and developing “living therapeutics” using its Afibromer technology product platform.
Health technology and clinical wearables are hot topics in the healthcare and pharmaceutical industries. They are creating waves of excitement and talking points for debate, while also topping many of the healthcare trends of this year.
The European Medicines Agency (EMA) has accepted for review Sanofi’s regulatory submission for sotagliflozin. If approved, the oral treatment would be used as an addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes mellitus.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.